TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

BRINSUPRI

BRENSOCATIB
Respiratory Approved 2025-08-12
1
Indication
--
Phase 3 Trials
1
Priority Reviews
0
Years on Market

Details

Status
Prescription
First Approved
2025-08-12
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: BRENSOCATIB

BRINSUPRI Approval History

Loading approval history...

What BRINSUPRI Treats

1 indications

BRINSUPRI is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bronchiectasis
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BRINSUPRI FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.

BRINSUPRI Patents & Exclusivity

Latest Patent: Feb 2040
Exclusivity: Aug 2030

Patents (56 active)

US12059424 Expires Feb 21, 2040
US12201638 Expires Mar 1, 2039
US9522894 Expires Mar 12, 2035
US12054465 Expires Jan 21, 2035
US11814359 Expires Jan 21, 2035
US11773069 Expires Jan 21, 2035
US11673871 Expires Jan 21, 2035
US11655224 Expires Jan 21, 2035
US11655223 Expires Jan 21, 2035
US11655222 Expires Jan 21, 2035
+ 46 more patents

Exclusivity

NCE Until Aug 2030
NCE Until Aug 2030
NCE Until Aug 2030
NCE Until Aug 2030
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.